{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:38:31Z","timestamp":1765521511896,"version":"3.48.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) rarely presents as decompensated liver cirrhosis, posing a significant diagnostic challenge that can lead to misdiagnosis and delayed treatment. We report a case of kappa-light chain multiple myeloma (\u03ba-LCMM) initially managed as end-stage liver disease to highlight the diagnostic pathway and a successful, organ-reversing therapeutic outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a 67-year-old male who presented with decompensated liver cirrhosis and refractory ascites as the initial manifestation of multiple myeloma. Serum free light chain assay revealed a kappa level of 47,309.88 mg\/L, and bone marrow biopsy confirmed kappa-light chain multiple myeloma with 60% plasma cell infiltration. A profound clinical response, including reversal of hepato-renal dysfunction, was observed following targeted monotherapy with daratumumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case underscores the critical importance of including plasma cell dyscrasias in the differential diagnosis of unexplained cirrhosis, particularly when accompanied by decreased immunoglobulin levels. The serum free light chain assay is an essential tool for facilitating a timely diagnosis. Furthermore, our findings suggest that daratumumab monotherapy can be a safe and highly effective therapeutic strategy for achieving deep, durable responses and reversing severe organ damage in patients with multiple myeloma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1696746","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:34:44Z","timestamp":1765521284000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Daratumumab monotherapy in a patient with kappa light chain multiple myeloma and decompensated cirrhosis: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiying","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"217440","DOI":"10.1016\/j.canlet.2025.217440","article-title":"The burden of multiple myeloma in China: trends from 1990 to 2021 and forecasts for 2050","volume":"611","author":"Dou","year":"2025","journal-title":"Cancer Lett"},{"key":"B2","article-title":"Expression of phosphatidylinositol-3 kinase in bone marrow of patients with multiple myeloma and its clinical significance","volume":"22","author":"Ye","year":"2020","journal-title":"China Modern Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn1009-2137.2024.01.047","article-title":"Research progress on the mechanism of the PI3K\/AKT\/mTOR signaling pathway in multiple myeloma","volume":"32","author":"Liu","year":"2024","journal-title":"J Exp Hematology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3892\/mmr.2024.13314","article-title":"Carthamus tinctorius L. inhibits hepatic fibrosis and hepatic stellate cell activation by targeting the PI3K\/akt\/mTOR pathway","volume":"30","author":"Dong","year":"2024","journal-title":"Mol Med Rep"},{"key":"B5","article-title":"Relationship between serum levels of \u03b22-MG, CRP, and IL-6 and clinical stage in patients with multiple myeloma","volume":"43","author":"Han","year":"2021","journal-title":"Hebei Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.13455\/j.cnki.cjcor.113494-2024-2024-0223","article-title":"Value of combined detection of serum alkaline phosphatase, interleukin-6, and lactate dehydrogenase levels in the diagnosis of multiple myeloma","volume":"31","author":"Qiu","year":"2024","journal-title":"Chin J Clin Oncol Rehabilitation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176173","article-title":"Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation","volume":"12","author":"Kagan","year":"2017","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.2038","article-title":"Hepatic failure caused by plasma cell infiltration in multiple myeloma","volume":"15","author":"Rahhal","year":"2009","journal-title":"World J Gastroenterology : Wjg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1986.tb02543.x","article-title":"Systemic kappa light chain deposition and amyloidosis in multiple myeloma: novel morphological observations","volume":"10","author":"Kirkpatrick","year":"1986","journal-title":"Histopathology"},{"key":"B10","first-page":"1262","article-title":"Multiple myeloma presenting as liver cirrhosis: a case report","volume":"26","author":"Yang","year":"2011","journal-title":"Clin Focus"},{"key":"B11","article-title":"Multiple myeloma with gastrointestinal bleeding due to portal hypertension as the initial symptom: a case report","volume":"37","author":"Su","year":"2021","journal-title":"J Clin Hepatology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231563","article-title":"Rare case of acute on chronic hepatic failure in a patient with multiple myeloma-associated amyloidosis","volume":"13","author":"Muhammad Khan","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05911-9","article-title":"Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies","volume":"104","author":"Cassano","year":"2025","journal-title":"Ann Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220123","article-title":"Pulmonary Light-Chain Deposition Disease","volume":"42","author":"Sweet","year":"2022","journal-title":"Radiographics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"107368","DOI":"10.1016\/j.carpath.2021.107368","article-title":"Light chain deposition disease presenting as an atrial mass: a case report and review of literature","volume":"55","author":"Hudak","year":"2021","journal-title":"Cardiovasc Pathol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1358\/dot.2021.57.10.3313853","article-title":"Daratumumab for the treatment of multiple myeloma","volume":"57","author":"Goldsmith","year":"2021","journal-title":"Drugs Today (barcelona Spain: 1998)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"New Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2021.1971192","article-title":"Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease","volume":"28","author":"Kastritis","year":"2021","journal-title":"Amyloid"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1696746\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:34:46Z","timestamp":1765521286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1696746\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":18,"alternative-id":["10.3389\/fonc.2025.1696746"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1696746","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"1696746"}}